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Prevalence of tuberculosis in post-mortem studies of
HIV-infected adults and children in resource-limited
settings: a systematic review and meta-analysis
Rishi K. Guptaa, Sebastian B. Lucasb, Katherine L. Fieldingc and
Stephen D. Lawnd,e
Objectives: Tuberculosis (TB) is estimated to be the leading cause of HIV-related
deaths globally. However, since HIV-associated TB frequently remains unascertained,
we systematically reviewed autopsy studies to determine the true burden of TB at death.
Methods: We systematically searched Medline and Embase databases (to end 2013) for
literature reporting on health facility-based autopsy studies of HIV-infected adults and/
or children in resource-limited settings. Using forest plots and random-effects meta-
analysis, we summarized the TB prevalence found at autopsy and used meta-regression
to explore variables associated with autopsy TB prevalence.
Results: We included 36 eligible studies, reporting on 3237 autopsies. Autopsy TB
prevalence was extremely heterogeneous (range 0–64.4%), but was markedly higher in
adults [pooled prevalence 39.7%, 95% confidence interval (CI) 32.4–47.0%] com-
pared to children (pooled prevalence 4.5%, 95% CI 1.7–7.4%). Post-mortem TB
prevalence varied by world region, with pooled estimates in adults of 63.2% (95%
CI 57.7–68.7%) in South Asia (n¼2 studies); 43.2% (95% CI 38.0–48.3) in sub-
Saharan Africa (n¼9 studies); and 27.1% (95% CI 16.0–38.1%) in the Americas (n¼5
studies). Autopsy prevalence positively correlated with contemporary estimates of
national TB prevalence. TB in adults was disseminated in 87.9% (82.2–93.7%) of
cases and was considered the cause of death in 91.4% (95% CI 85.8–97.0%) of TB
cases. Overall, TB was the cause of death in 37.2% (95% CI 25.7–48.7%) of adult
HIV/AIDS-related deaths. TB remained undiagnosed at death in 45.8% (95% CI 32.6–
59.1%) of TB cases.
Conclusions: In resource-limited settings, TB accounts for approximately 40% of
facility-based HIV/AIDS-related adult deaths. Almost half of this disease remains
undiagnosed at the time of death. These findings highlight the critical need to improve
the prevention, diagnosis and treatment of HIV-associated TB globally.
Copyright  2015 Wolters Kluwer Health, Inc. All rights reserved.
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Introduction
Tuberculosis (TB) is estimated to be the leading cause of
HIV/AIDS-related deaths globally, with 1.1 million cases
of HIV-associated TB and 360 000 deaths in 2013 [1]. It is
further estimated that TB accounted for approximately
25% of all HIV/AIDS-related deaths worldwide in 2013,
and that sub-Saharan Africa accounted for almost 80% of
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this burden of morbidity and mortality [1,2]. This is
despite steady improvements in the implementation of
comprehensive strategies to reduce the burden of HIV-
associated TB [1,3], which are estimated to have saved 1.3
million lives between 2004 and 2012 [2]. However,
estimates of TB disease burden and associated deaths are
largely based on modelling of data originally derived from
clinical records, death certificates, notification data and
verbal autopsies, all of which are inaccurate [4].
Early in the HIV epidemic, autopsy studies played a key
role in establishing the range and frequency of
opportunistic infections and other diseases [5], and
autopsy still remains the gold-standard method of
ascertaining causes of death. Marked discordance
between pre-mortem and post-mortem diagnoses has
been observed in HIV-infected patients even in high-
income settings [6]. This discrepancy is likely to be even
more marked in resource-limited settings due to
limitations in laboratory facilities and radiological
capacity. Diagnosis of TB is particularly difficult in the
context of HIV co-infection due to atypical, non-specific
clinical presentation and reduced sensitivity of widely
used routine diagnostic tests [7]. Autopsy studies therefore
have a key role in determining the frequency of TB as a
cause of death in HIV-infected patients.
Although a growing number of autopsy studies have been
conducted over the past 20 years to determine causes of
death in HIV-infected individuals in resource-limited
settings, and narrative reviews of studies from Africa have
been published [8,9], this literature has not previously
been reviewed systematically and synthesized quantitat-
ively using meta-analysis. The purpose of this systematic
review and meta-analysis was to summarize prevalence of
TB found in health facility-based autopsy studies of HIV-
infected patients in low and middle-income settings
worldwide. We further aimed to explore how prevalence
varied by age (adults versus children), geographic region
and contemporary estimates of both national TB and HIV
prevalence and study year [the latter being used as a proxy
for antiretroviral therapy (ART) scale-up]. We also sought
to summarize the anatomic sites of TB disease found in
these studies and the proportions of TB cases that
remained undiagnosed at the time of death.
Methods
Search strategy
We searched Medline and Embase databases for autopsy
studies done in HIV-infected adults and/or children in
low and middle-income countries (as defined by the
World Bank on 23 December 2013) and published by
December 2013. The search strategy (Supplementary
Table 1, http://links.lww.com/QAD/A748) was pre-
specified in the review protocol. In brief, three search sets
were created and then combined using ‘and’; these
included comprehensive search terms for autopsy, for
HIV/AIDS and for TB. References of individual studies
and review articles were also hand-searched, and experts
in the field were consulted to suggest additional articles.
In addition, abstract books from the International Union
Against Tuberculosis and Lung Disease were hand-
searched for a 10-year period (2004–2013), and abstracts
from the International AIDS Society Conferences on
HIV Pathogenesis and Treatment and International AIDS
Conferences were electronically searched from 2001 to
2013. Studies identified by the searches were compiled
into a database and duplicates were removed. Citations
were initially screened by title and abstract to assess for
potential eligibility. Full-texts of those deemed potentially
eligible were then obtained and reviewed. This review
was conducted with adherence to the PRISMA checklist
[10]. Research Ethics Committee permission was not
required as this was a secondary analysis of published
anonymized data.
Study selection
Studies identified in the literature search were eligible for
inclusion if they entailed at least 10 autopsies (either full or
limited) of HIV-infected adults or children, if they
reported the prevalence of TB amongst those autopsied
and were conducted in a low or middle-income country.
Studies were excluded if patients were pre-selected
according to a specific clinical ante-mortem diagnosis
(e.g. TB) or if they studied specific sub-populations with
potentially limited generalizability (e.g. deaths among
pregnant women or among mine workers). Single-organ
autopsy studies were only included if this organ was the
lung. If multiple reports were derived from the same study
population, only the largest study was included. Authors
of studies which reported on both HIV-infected and
uninfected patients were contacted to provide data
disaggregated by HIV status; studies for which disag-
gregated data were not obtained were excluded. Non-
English articles were included if they had an abstract in
English that provided sufficient information to meet the
above inclusion criteria. Authors of studies that reported
aggregated data from both adults and children or that did
not specify the ages of the study participants were
contacted and asked to provide appropriately stratified
data.
Data extraction
Data were extracted directly into a spreadsheet that
included the following variables: title, authors, year of
study, year of publication, location, estimates of the
prevalence of TB and of HIV in country at time of study
[using WHO and Joint United Nations Programme on
HIV/AIDS (UNAIDS) estimates], study setting, study
population, need for consent for autopsy; the total
number of deaths potentially available for autopsy; the
autopsy rate (the proportion of eligible subjects in whom
an autopsy was done); the number of HIV-positive adults
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autopsied, number of HIV-positive children autopsied;
demographics of patients; CD4þ cell counts and ART
status. The following were also recorded regarding the
autopsy methods and findings: autopsy type and methods,
post-mortem TB case definition, proportion of patients
with TB found at autopsy, proportion of patients in
whom TB was identified as the primary cause of death,
organs involved with TB at autopsy and correlation of
clinical and autopsy diagnoses.
The primary outcome was the prevalence of TB at
autopsy. Other outcomes of interest included the
anatomical site of TB disease, and the proportion of
autopsy-confirmed TB cases that were undiagnosed pre
mortem. Study quality was assessed using a pre-specified,
graded checklist (Supplementary Table 2, http://links.
lww.com/QAD/A748); studies were considered to be of
‘good quality’ if they scored at least 70% of points;
‘medium quality’ if they scored 40–69%; and ‘lower
quality’ if they scored below 40%.
Analyses
Forest plots displaying the prevalence of TB at post
mortem were generated for all included studies and then
for studies stratified by age and geographical region.
Pooled estimates were obtained using a random-effects
model, and heterogeneity of outcomes was assessed
through calculation of I-squared statistics for each of the
groups of studies. A fixed continuity correction was used
for studies which had 0 or 100% outcomes. When meta-
analysis was not appropriate to use, summary measures
were calculated instead as medians and ranges. Scatter
plots and meta-regression were used to examine the
relationships between the post-mortem TB prevalence
found in each study and the estimated national TB
prevalence and national HIV prevalence at the time the
study was conducted, along with the year at the midpoint
of the study (the latter serving as a proxy for ART scale-
up). All analyses were done using Stata 13.0 (StataCorp,
College Station, Texas, USA).
Results
Characteristics of studies included
A total of 36 studies (reported in 32 papers and four
conference abstracts) were included (Fig. 1). Of these, 16
reported on adult patients only, others reported on
children only (n¼ 10) and the remainder either reported
on both adults and children or on patients of unspecified
age (n¼ 10) (Table 1). Among the latter, disaggregated
data were provided by the authors of one of these studies;
however, since only six of 46 patients were children, only
the adult data were included in these analyses [11]. This
review includes data from a total of 3237 autopsies. Of
these, 1562 autopsies were of adults, 704 were of children,
and a further 971 autopsies were of patients whose age
remained unclassified.
Of the 36 studies included, 20 were done in sub-Saharan
Africa, eight in the Americas, four in East Asia and four in
South Asia (Table 1). The population prevalence of TB at
the time of the studies ranged between 87 and 851 cases
per 100 000 population, and HIV prevalence ranged from
0.1 to 26.8% (Table 1). Autopsies were primarily done in
patients who died as hospital in-patients (29 studies); a
small proportion of studies included some community-
based deaths (n¼ 2) [12,13], but this variable was
unspecified in five studies.
Consent (from families or patients prior to death) was
required for autopsy in 18 of 36 (50%) of the included
studies. The total number of deaths considered for
possible autopsy was stated in 15 studies, allowing the
autopsy rate to be calculated (median 28.8%; range
4–97.5%). The mean/median age of patients autopsied
was specified in 22 studies, ranging from 31.3 to 40 years
in adults and from 3months to 5.9 years in children. Only
five studies reported the CD4þ cell counts of patients,
with the mean/median ranging from 50 to 87 cells/ml. In
each of four studies [14–17], a proportion of patients was
receiving ART at the time of death (range 17–100%).
Autopsy methods were specified in 32 studies (Table 1);
13 did full autopsies, including the brain; eight others did
full autopsies, but did not specify whether the brain was
examined; another study did full autopsies, but excluded
the brain and 10 studies performed limited autopsies. The
method of confirming TB at autopsy was specified in 29
studies. TB diagnosis in 26 of these studies was based on
histopathological appearances and staining for acid-fast
bacilli (AFB) (six of these studies additionally used TB
culture and/or TB PCRtesting); 2 studies made TB
diagnoses using case conference reviews of the clinical
history, autopsy and microbiology data [14,17]; 1 study
used AFB microscopy and culture only [16]. The median
number of autopsies in each study was 62 (range 16–250).
A total of 11 studies were assessed as being of good
quality, 15 of medium quality and 10 of lower quality
(Table 1).
Prevalence of tuberculosis at autopsy
The prevalence of TB in HIV-infected patients at autopsy
was extremely heterogeneous, ranging from 0 to 64.4%
(median 27.7%) (Fig. 2a). A stratified plot shows that TB
prevalence was strongly associated with age category
(Fig. 2b). We used meta-analysis to generate pooled
summary prevalence estimates for adults [39.7%, 95%
confidence interval (CI) 32.4–47.0%] and for children in
whom pooled prevalence was much lower (4.5%, 95% CI
1.7–7.4%). Of note, the pooled summary proportion of
TB cases among adults who remained undiagnosed pre
mortem was 45.8% [95% CI 32.6–59.1%).
Among studies reporting on adults, the prevalence of
TB at autopsy varied markedly by geographic region. The
pooled prevalence was 63.2% (95% CI 57.7–68.7%)
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for studies in South Asia (n¼ 2); 43.2% (95% CI 38.0–
48.3%) in studies in sub-Saharan Africa (n¼ 9), 27.1%
(95% CI 16.0–38.1%) in studies in the Americas (n¼ 5)
and 12.5% in a single study from East Asia (Fig. 2c).
Among studies of children, just two reported a TB
prevalence that exceeded 10% (11 and 18%), and both of
these were from the southern African region [18,19].
Meta-regression analyses
Using meta-regression analysis, higher prevalence of TB
at autopsy was found to be positively associated with a
greater national population TB prevalence estimate at the
time of the study (Fig. 3a). In crude analysis, an increase in
national TB prevalence of 200 per 100 000 was associated
with a 6.5% (95% CI 0.3–12.7%, P¼ 0.04) increase in
post-mortem TB prevalence. Similarly, autopsy TB
prevalence tended to be higher in studies done in
countries with higher HIV prevalence, but this relation-
ship did not reach statistical significance (Fig. 3b). In
studies done in sub-Saharan Africa in adults, autopsy TB
prevalence tended to increase over the 20-year period
between 1992 and 2012 (Fig. 3c), with an approximately
5% greater post-mortem prevalence for an increase in
each 10-year period (5.6%, 95% CI 0.0–11.3%,
P¼ 0.05). Studies with higher-quality assessment scores
also tended to report higher autopsy TB prevalence
(Fig. 3d), with a 4.7% greater TB prevalence for every
4 points higher score, but this relationship did not reach
statistical significance (P¼ 0.37).
Sensitivity analysis for potential selection bias in
autopsy studies
Bias in autopsy studies during selection of individuals for
study inclusion could potentially have enriched the
proportion with TB. We examined studies from Africa
(n¼ 4) in which the medical in-patients studied were
considered to be at very low risk of selection bias. Among
these, the pooled post-mortem prevalence of TB was
48.1% (95% CI 39.1–57.1%) [14,16,20,21], which did
not differ from the pooled summary estimate of 43.2%
(95% CI 38.0–48.3) for all studies of adults in Africa
(n¼ 9).
Tuberculosis dissemination
A total of 12 studies (Table 2) described the proportion of
adult TB cases in which disease was disseminated (pooled
1990 AIDS 2015, Vol 29 No 15
835 potentially relevant citations identified from electronic databases
(347 from Medline / 488 from Embase)
137 potentially relevant citations identified from conference abstract books
4 potentially relevant citations identified from reference lists
92 selected for full-text review
884 excluded after first screen
- 343 duplicates
- 541 on basis of title / abstract
36 studies included in review
56 excluded after full-text review
- 16 included data that overlapped with a larger
study
- 10 were single-organ studies (not lungs)
- 9 did not describe the post-mortem prevalence
of TB
- 6 review articles
- 5 included individuals restricted to one specific
diagnosis
- 2 included HIV-negative subjects
- 2 restricted to specific subpopulations (maternal
deaths, miners)
- 2 restricted to ‘forensic’ autopsy cases
- 1 had no English abstract or full paper available
- 1 included < 10 patients
- 1 done in a high-income country
- 1 analysed ante-and post-mortem biopsy
samples together
Fig. 1. Flow diagram showing study selection process and reasons for exclusions.
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summary proportion 87.9%, 95% CI 82.2–93.7%), but
specific details of which organs were involved was
inconsistently reported (Table 2). The organs most
frequently involved were the lungs (median 85% of TB
cases; range 56–98%; n¼ 4 studies), spleen (median 83%
of TB cases; range 81–84%; n¼ 5 studies), liver (median
79% of TB cases; range 69–88%; n¼ 5 studies), and
lymph nodes (median 75% of TB cases; range 56-86%;
n¼ 4 studies). The central nervous system was less
frequently involved with a median of 20% of TB cases
(range 10–25%; n¼ 5 studies).
Tuberculosis as primary cause of death
A total of 12 studies overall described ‘both’ the
prevalence of TB at autopsy and the proportion of
patients in whom TB was the primary cause of death
(Table 2). Among 10 studies of adults, TB was the
primary cause of death in a pooled proportion of 91.4%
(95% CI 85.8–97.0%) of cases where it was present. The
overall proportion of HIV-related deaths for which TB
was identified as the primary cause of death was reported
by 10 studies done in adults (pooled summary proportion
37.2%, 95% CI 25.7–48.7%).
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Fig. 2a. Forest plots showing post-mortem prevalence [% (95% CI)] of tuberculosis (TB) in the following as given in the legend.
Fig. 2(a). All studies included in the review ordered by prevalence (n¼36 studies; 3237 autopsies included).
(b) All studies stratified by age category of patients: adults/children/mixed or unspecified (n36 studies; 3237 autopsies included).
(c) Studies of adults only, stratified by world region: Africa/South Asia / East Asia / Americas (n¼17 studies; 1562 autopsies
included). Pooled summary estimates generated by using a random-effects meta-analysis are shown for each of the three age
classifications (‘adults’, ‘children’ and ‘mixed or unspecified’) and for each of the four geographic regions (Africa, South Asia, East
Asia and the Americas). CI, confidence interval. () Studies that presented the proportion of patients in which TB was regarded as
the primary cause of death at autopsy.
Discussion
This is the first systematic literature review and meta-
analysis of the burden of TB diagnosed by autopsy studies
of HIV-infected adults and children in resource-limited
settings worldwide. The overall prevalence of TB in
adults and children was huge and accounted for almost
40% of HIV-related facility-based deaths in adults. This is
greater than the WHO/UNAIDS estimate that overall
TB accounts for approximately 25% of HIV/AIDS-
related deaths worldwide. In the present review, TB was
regarded as the primary cause of death in 91.4% (85.8–
97.0%) of cadavers in which it was present. Thus,
consistent with other data [48], these autopsy studies
strongly indicate that TB was directly contributing to
mortality in HIV-infected patients, rather than simply
being present as a marker of advanced immunodeficiency,
like oral candidiasis. The prevalence among adults was
particularly high in South Asia and Africa, where
approximately 63 and 43% of adults had evidence of
TB at autopsy, respectively. A pooled proportion of 45.8%
(32.6–59.1%) of confirmed TB cases identified at autopsy
remained undiagnosed at the time of death. These
findings highlight the critical need for improvements in
the prevention, diagnosis and management of HIV-
associated TB.
Our findings were drawn from a large number of studies
from around the world, contributing data on a total of
3237 autopsies of adults and children. Although TB
prevalence at autopsy varied substantially between the 36
studies, we showed that age group (adults versus children)
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Fig. 2b. (Continued ).
and geographic region were strongly associated factors.
Other sources of heterogeneity potentially include the
variable size of the studies, with the number of autopsies
done ranging between 16 and 250. Different methods and
case definitions were used to diagnose TB. In addition,
although the vast majority of autopsy studies donewere of
hospital in-patients, a minority were of community-based
deaths. Although the prevalence of TB among adult
deaths in South Asia was extremely high, there were only
two studies from this region and both were from the city
of Mumbai, and therefore may not be representative of
the rest of the Indian sub-continent. In contrast, far more
data were available for sub-Saharan Africa, with multiple
studies from countries located across west, east and
southern Africa.
In only a minority of the 36 studies was it explicitly clear
that consecutive, unselected HIV-infected in-patient
deaths were studied. Moreover, in some studies, the
autopsy rate was low. Thus, it is unclear towhat extent the
data included are truly representative of deaths in HIV-
infected adults and children. Patient selection for autopsy
might potentially enrich the proportion with TB in those
studied. However, in a sensitivity analysis of studies
(n¼ 4) conducted in Africa in which recruitment was
considered to be at very low risk of selection bias, the
pooled TB prevalence was actually higher (48.1%, [95%
CI 39.1–57.1%) than that of all studies from the region.
Thus, we found no evidence that might suggest that
prevalence rates were high due to selection bias. Since
embarking on this review and meta-analysis, one further
post-mortem study from a tertiary referral hospital in
Zambia has been published [49]. The data in this
additional study are entirely consistent with the findings
of this systematic review, and its inclusion would not have
altered any of the summary estimates in our meta-analysis.
In the vast majority of HIV-TB cases in adults [pooled
summary estimate 87.9% (82.2–93.7%) of TB cases),
disease was disseminated, with the lungs, spleen, liver and
lymph nodes being the most commonly involved organs
at autopsy. This highlights the widespread extent of TB
disease in patients with advanced HIV-related immuno-
deficiency and suggests that microbiological diagnosis
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need not rest solely on examination of respiratory
samples. Almost one half [pooled proportion 45.8%
(32.6–59.1%)] of confirmed TB cases identified at
autopsy remained undiagnosed at the time of death,
highlighting current critical limitations in approaches to
TB diagnosis. The presentation of HIV-associated TB is
often atypical or it may remain sub-clinical. This is
compounded by the fact that sputum-based diagnosis is
less sensitive in patients with HIV co-infection. This has
lead to the development of management algorithms for
suspected smear-negative TB [50] and research exploring
strategies of systematically starting empirical TB treat-
ment for those with advanced HIV who are at greatest
risk of disease [51], such as the ACTG REMEMBER
Trial (NCT01380080).
Much progress, however, has been made in recent years in
the development of novel diagnostic tools for TB. The
Xpert MTB/RIF assay (Cepheid, Sunnyvale, California,
USA) is a semi-automated nucleic acid amplification test
that can detect Mycobacterium tuberculosis and the presence
of mutations conferring rifampicin resistance in less than
2 h [52]. It was endorsed by the WHO in 2010 as the
initial diagnostic test for suspected HIV-associated
pulmonary TB and for multidrug-resistant pulmonary
TB in adults [53]. With a growing evidence base [54,55],
this guidance has since been extended to include
investigation of children and also the testing of non-
respiratory samples to diagnose extra-pulmonary forms of
TB [56]. The Xpert MTB/RIF assay provides a
substantially higher sensitivity than sputum smear
microscopy for TB diagnosis during active screening of
patients with advanced HIV-associated immunodefi-
ciency [57] and can also be used to screen non-respiratory
samples, such as urine, from these patients [58].
Lipoarabinomannan (LAM) is a mycobacterial cell wall
antigen for which a low-cost, point-of-care, lateral-flow
assay has been developed (Determine TB-LAM Ag; Alere
Inc. Waltham, Massachusetts, USA), allowing rapid TB
diagnosis to be made from urine samples [59]. Although
limited, sensitivity is highest in those with the most
Autopsy prevalence of HIV-associated tuberculosis Gupta et al. 1997
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Fig. 3. Meta-regression analyses showing graphs of post-mortem prevalence of tuberculosis (Y-axis) plotted against the
following. (a) The study mid-point national population tuberculosis prevalence estimate (X-axis) in autopsy studies of adults
only (n¼17); and (b) the study mid-point national HIV prevalence; (c) year of the study mid-point (X-axis) for studies of adults in
sub-Saharan Africa (n¼9); (d) quality assessment score (X-axis) for studies of adults in sub-Saharan Africa (n¼9).
1998 AIDS 2015, Vol 29 No 15
T
ab
le
2
.
P
re
va
le
n
ce
an
d
ch
ar
ac
te
ri
st
ic
s
o
f
p
o
st
-m
o
rt
em
tu
b
er
cu
lo
si
s
ca
se
s
in
in
cl
u
d
ed
st
u
d
ie
s.
A
u
th
o
rs
A
u
to
p
si
es
T
B
D
is
se
m
in
at
ed
O
rg
an
s
in
vo
lv
ed
in
T
B
ca
se
s
T
B
ca
se
s
u
n
d
ia
gn
o
se
d
an
te
m
o
rt
em
T
B
ca
se
s
w
h
er
e
T
B
re
ga
rd
ed
ca
u
se
o
f
d
ea
th
St
u
d
ie
s
in
ad
u
lt
s
A
b
o
u
ya
et
al
.
(1
9
9
2
)
[2
2
]
5
3
2
1
(3
9
.6
%
)
1
9
/2
1
(9
0
%
)
2
1
/2
1
(1
0
0
%
)
A
m
ar
ap
u
rk
ar
et
al
.
(2
0
0
5
)
[2
3
]
6
0
3
5
(5
8
.3
%
)
1
8
/3
5
(5
1
%
)
2
3
/3
5
(6
6
%
)
3
5
/3
5
(1
0
0
%
)
A
n
sa
ri
et
al
.
(2
0
0
2
)
[2
4
]
1
0
4
4
2
(4
0
.4
%
)
3
7
/4
2
(8
8
%
)
Lu
n
gs
4
1
/4
2
(9
8
%
);
sp
le
en
3
5
/4
2
(8
3
%
);
li
ve
r
3
4
/4
2
(8
1
%
);
ly
m
p
h
n
o
d
es
3
4
/4
2
(8
1
%
);
ki
d
n
ey
2
2
/4
2
(5
2
%
);
ga
st
ro
in
te
st
in
al
1
8
/4
2
(4
3
%
);
b
o
n
e
m
ar
ro
w
1
0
/4
2
(2
4
%
);
ce
n
tr
al
n
er
vo
u
s
sy
st
em
4
/4
2
(1
0
%
)
5
/3
7
(1
4
%
)
3
8
/4
2
(9
0
%
)
B
o
rg
es
et
al
.
(1
9
9
7
)
[2
5
]
5
2
9
(1
7
.3
%
)
6
/9
(6
7
%
)
C
o
h
en
et
al
.
(2
0
1
0
)
[1
6
]
2
2
6
1
0
6
(4
6
.9
%
)
4
6
/1
1
0
(4
2
%
)a
C
o
x
et
al
.
(2
0
1
2
)
[1
5
]
3
5
1
6
(4
5
.7
%
)
1
6
/1
6
(1
0
0
%
)
Sp
le
en
1
3
/1
6
(8
1
%
);
li
ve
r
1
1
/1
6
(6
9
%
);
ly
m
p
h
n
o
d
es
1
1
/1
6
(6
9
%
);
lu
n
gs
9
/1
6
(5
6
%
)
5
/1
6
(3
1
%
)
1
3
/1
6
(8
1
%
)
C
u
ry
et
al
.
(2
0
0
3
)
[2
6
]
9
2
2
5
(2
7
.2
%
)
1
7
/2
5
(6
8
%
)
Ez
a
et
al
.
(2
0
0
6
)
[2
7
]
1
6
2
(1
2
.5
%
)
2
/2
(1
0
0
%
)
Li
ve
r
2
/2
(1
0
0
%
);
o
es
o
p
h
ag
u
s
2
/2
(1
0
0
%
);
ly
m
p
h
n
o
d
es
2
/2
(1
0
0
%
);
lu
n
gs
2
/2
(1
0
0
%
);
ki
d
n
ey
1
/2
(5
0
%
);
sp
le
en
1
/2
(5
0
%
);
ad
re
n
al
1
/2
(5
0
%
);
th
yr
o
id
1
/2
(5
0
%
);
ge
n
it
o
u
ri
n
ar
y
1
/2
(5
0
%
)
1
/2
(5
0
%
)
2
/2
(1
0
0
%
)
H
si
ao
et
al
.
(1
9
9
7
)
[2
8
]
1
6
2
(1
2
.5
%
)
2
/2
(1
0
0
%
)
1
/2
(5
0
%
)
Je
ss
u
ru
n
et
al
.
(1
9
9
0
)
[2
9
]
5
8
1
6
(2
7
.6
%
)
La
n
je
w
ar
(2
0
1
1
)
[3
1
]
2
3
6
1
5
2
(6
4
.4
%
)
1
4
3
/1
5
2
(9
4
%
)
Ly
m
p
h
n
o
d
es
1
3
1
/1
5
2
(8
6
%
);
sp
le
en
1
2
7
/1
5
2
(8
4
%
);
li
ve
r
1
1
8
/1
5
2
(7
8
%
);
ki
d
n
ey
8
7
/1
5
2
(5
7
%
);
ce
n
tr
al
n
er
vo
u
s
sy
st
em
2
9
/1
5
2
(1
9
%
)
1
4
9
/1
5
2
(9
8
%
)
Lu
ca
s
et
al
.
(1
9
9
3
)
[2
0
]
2
4
7
9
4
(3
8
.1
%
)
8
4
/9
4
(8
9
%
)
Lu
n
gs
8
8
/9
4
(9
4
%
);
ce
n
tr
al
n
er
vo
u
s
sy
st
em
1
9
/9
4
(2
0
%
);
ga
st
ro
in
te
st
in
al
1
9
/9
4
(2
0
%
)
8
0
/9
4
(8
5
%
)
M
ar
q
u
es
et
al
.
(1
9
9
6
)
[1
1
]
4
0
2
1
(5
2
.5
%
)
1
6
/2
1
(7
6
%
)
K
id
n
ey
1
1
/2
1
(5
2
%
);
ly
m
p
h
n
o
d
es
3
/2
5
(1
2
%
)
N
el
so
n
et
al
.
(1
9
9
3
)
[3
2
]
6
4
2
6
(4
0
.6
%
)
2
6
/2
6
(1
0
0
%
)
1
3
/2
6
(5
0
%
)
R
an
a
et
al
.
(2
0
0
0
)
[2
1
]
7
5
3
8
(5
0
.7
%
)
3
1
/3
8
(8
2
%
)
Sp
le
en
3
1
/3
8
(8
2
%
);
li
ve
r
3
0
/3
8
(7
9
%
);
ki
d
n
ey
1
6
/3
8
(4
2
%
);
ga
st
ro
in
te
st
in
al
1
1
/3
8
(2
9
%
);
ce
n
tr
al
n
er
vo
u
s
sy
st
em
9
/3
8
(2
4
%
)
1
7
/3
7
(4
6
%
)
3
5
/3
8
(9
2
%
)
Si
ik
a
et
al
.
(2
0
1
2
)
[1
7
]
1
4
9
5
0
(3
3
.6
%
)a
W
o
n
g
et
al
.
(2
0
1
2
)
[1
4
]
3
9
2
5
(6
4
.1
%
)
2
4
/2
5
(9
6
%
)
Li
ve
r
2
2
/2
5
(8
8
%
);
sp
le
en
2
1
/2
5
(8
4
%
);
lu
n
gs
1
9
/2
5
(7
6
%
);
ly
m
p
h
n
o
d
es
1
4
/2
5
(5
6
%
);
ce
n
tr
al
n
er
vo
u
s
sy
st
em
5
/2
5
(2
5
%
);
re
n
al
1
1
/2
5
(4
4
%
);
b
o
n
e
m
ar
ro
w
1
6
/2
5
(6
4
%
);
p
le
u
ra
3
/2
5
(1
2
%
)
8
/2
5
(3
2
%
)
1
4
/2
5
(5
6
%
)
St
u
d
ie
s
in
ch
il
d
re
n
A
n
sa
ri
et
al
.
(2
0
0
3
)
[1
9
]
3
5
4
(1
1
.4
%
)
4
/4
(1
0
0
%
)
Ly
m
p
h
n
o
d
es
3
/4
(7
5
%
);
sp
le
en
3
/4
(7
5
%
);
ge
n
it
o
u
ri
n
ar
y
2
/4
(5
0
%
),
ga
st
ro
in
te
st
in
al
1
/4
(2
5
%
)
4
/4
(1
0
0
%
)
B
h
o
o
p
at
et
al
.
(1
9
9
4
)
[3
3
]
2
9
1
(3
.4
%
)
0
/1
(0
%
)
C
h
ak
ra
b
o
rt
y
et
al
.
(2
0
0
2
)
[1
3
]
3
3
1
(3
.0
%
)
1
/1
(1
0
0
%
)
0
/1
(0
%
)
1
/1
(1
0
0
%
)
C
h
in
tu
et
al
.
(2
0
1
2
)
[1
8
]
1
8
0
3
2
(1
7
.8
%
)
1
0
/5
4
(1
9
%
)
D
ru
t
et
al
.
(1
9
9
7
)
[3
4
]
7
4
1
(1
.4
%
)
advanced HIV-associated immunodeficiency [59] and
worst prognostic characteristics [60]. Thus, the assay has
potential to be used as a screening tool for the large burden
of undiagnosed disseminated TB among HIV-infected
medical in-patients [61]. WHO is to review the growing
evidence base for the assay in 2015.Urine can also be tested
using the Xpert MTB/RIF assay, providing a useful
diagnostic yield among patients with advanced immuno-
deficiency [58,62]. Intervention trials of urine-based
screening among HIV-infected in-patients in hospitals in
southern Africa are ongoing, including the LAMRCT
(NCT01770730) and STAMP (ISRCTN71603869)
trials.
The global scale-up of ART had provided treatment for
an estimated 12.9 million people by 2013. However, this
represented just 38% of those eligible for ART under
WHO guidelines [63]. Despite ART scale-up, the
prevalence of TB at autopsy in HIV-infected adults has
remained high, with prevalence estimates of 34–64% in
the four studies which have been done in Africa during
the ART era [14–17]. Thus, we observed no reduction
over time in the prevalence of TB found in autopsy
studies done in sub-Saharan Africa between 1992 and
2012. Although ART reduces TB risk among patients
across all CD4þ strata [64], therapy is all too often started
too late [65]. Patients continue to present to the
healthcare service with advanced immunodeficiency
and high risk of TB and death. Further scale-up of
ART through expanded HIV testing and timely ART
initiation at higher CD4þ cell count thresholds are vital
for more effective prevention of HIV-TB and associated
deaths. Other effective interventions for prevention of
HIV-associated TB, such as provision of isoniazid
preventive therapy, also require further scale-up [2,66].
We found that the prevalence of TB at autopsy was much
lower in HIV-infected children than in adults, and
exceeded 10% in just two studies of children in southern
Africa [18,19]. There are no global estimates available for
TB incidence and mortality in HIV-infected children [1].
There were an estimated 550 000 new paediatric TB cases
worldwide in 2013, and cohort studies in high TB burden
countries have found a prevalence of HIV of 16–56%
among such cases [1,67]. While the burden of disease
found in HIV-infected children is much less than that in
adults, additional work is needed to establish the true
burden of disease at a global level.
Strengths of this study include the fact that it is the first
systematic review and meta-analysis to be done of autopsy
studies in HIV-infected patients in resource-limited
settings at a global level and the fact that both adults
and children were included. This is also the first review to
evaluate site of TB disease among HIV-infected cadavers
across studies. Limitations include the fact that few studies
had been conducted in some global regions, such as south
and south-east Asia.
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.
In conclusion, this study has quantified the huge burden
of TB found at autopsy of HIV-infected adults in
resource-limited settings, illustrating that TB remains the
most important opportunistic infection in people living
with HIV. In addition, almost half of this disease
remained undiagnosed at the time of death, and the
prevalence of TB in autopsy studies of HIV-infected
adults in studies done in Africa has tended to increase
rather than decrease over a 20-year period, highlighting
the ongoing failure of current prevention, case detection
and treatment strategies. Further scale-up and timely
initiation of ART is key in preventing HIV-associated
TB. Development of screening algorithms and effective
implementation of novel diagnostic tools is required to
allow early case detection of HIV-TB and reduce
mortality through early treatment initiation, when
prevention fails.
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